
The Maladjusted Foal







Jon Palmer, VMD

Changes in Behavior











Neonatal Intensive Care



Hypoxic-Ischemic Syndrome

Human Neonates - cerebral palsy

- Prolonged Stage II
- Lawsuits
- Clinical studies on onset
 - Intranatal
 - Prenatal
 - Postnatal
- Experimental Studies
 - Hypoxic ischemic insults
 - Hypoxic ischemic encephalopathy (HIE)



Neonatal Problems

Selective neuronal pathology
Renal pathology
Gastrointestinal pathology
Metabolic failure
Cardiovascular pathology
Endocrine abnormalities



Neonatal Problems


Hypoxic ischemic asphyxial disease?
Often no evidence
Inflammatory placental disease
Strong correlation
Role of inflammatory mediators?
Cytokines, local vasoactive mediators
Primary effect?
Secondary hypoxic ischemic insult?



Role of Placentitis

Many neonatal diseases Multiple etiologies Disruption of fetal life Predispose to neonatal disease Origin of the neonatal disease Placentitis - untreated Neonatal diseases CNS, Renal, GI Placentitis - treated Protects against neonatal diseases





The Maladjusted Foal

Dummies

Barkers

Wanders


Hypoxic Ischemic Syndrome Perinatal Asphyxia Hypoxic Ischemic Asphyxial Syndrome Neonatal Multisystem Maladaptation

Terms Generic Description of Signs Neonatal Encephalopathy (NE) Neonatal Gastroenteropathy (NG) Neonatal Nephropathy (NN) Neonatal Metabolic Maladaptation Neonatal Cardiovascular Maladaptation

Intrauterine Challenge

Indications at birth of intrauterine challenge Cr level Hypochloremic alkalosis High PCV Persistently low blood glucose Ca levels Fibrinogen level **WBC** Low cortisol Lactate level

Fetal foal floating in a sea of creatinine







Thoroughbred foal Born: May 7 at 6 PM Admitted: May 8 at 8:53 AM 15 hrs old



Term birth to a multiparas mare Normal gestation Stage 1 - not observed Stage 2 - 10 minutes or less Stage 3 - 1 hour Assisted to stand after 1.5 hours Nursed from the mare



Never vigorous Got up once during night Only for short time Did not nurse Bottle-fed 8 oz. of colostrum Referred for intensive care Weak Inability to stand

"Pong" Admission Physical

Marked oral, nasal, scleral, aural icterus
Oral, nasal, scleral, aural injection

- Multiple oral petechia
- Marked lingual erythema
- Abdomen
 - Meconium in the right dorsal colon
 - Few borborygmi
 - Fetal/neonatal diarrhea

"Pong" Admission Physical



"Pong" Admission Problems

- Weakness, somnolence
 Not nursing
 Lingual erythema
 Injection
 Petechia
 Icterus
 Poor perfusion
- Diarrhea
- ► **₩BC**,
 - **↑**fibrinogen
- ► ↑ PCV, ↑ TPP
- Creatinine
- Hypoxemia
- h lactate

"Pong" Major Problems



Periods - bright and active
Sudden onset of somnolence

Somnolence/ periods of arousal

Apparent facial paresis

Right ear moves slowly

Generalized weakness

Periodic apnea
Up to 60 sec
With clustered breathing
Inappropriate central tachypnea
Apneusis (apneustic respiration)
Hypercapnia
Without apnea

Seizure like activity
Opisthotonus, tonic/clonic marching activity
Minimal nystagmus
Hyperresponsive to stimuli
No suckle or searching

Neonatal Encephalopathy CNS Signs

Most common and noticeable

- Signs occur predictably 90%
- Mild central insult
 - Multifocal lesions
 - Selective neuronal dysfunction
 - Slow maturation of coordination



Changes in responsiveness
Changes in muscle tone
Changes in behavior
Signs of brain stem damage
Seizure-like behavior
Coma, death

Changes in responsiveness Hyperesthesia Hyperresponsiveness Hyperexcitability Hyporesponsiveness Periods of somnolence Unresponsiveness





Changes in muscle tone
Extensor tonus
Hypotonia
Neurogenic myotonia
Inability to protract legs






Changes in behavior

- Loss of suckle response
- Loss of tongue curl
- Loss of tongue coordination
- Disorientation especially relative to the udder
- Aimless wandering
- Blindness
- Loss of affinity for the dam
- Abnormal vocalization ("barker")

Changes in behavior





Changes in respiratory patterns Central tachypnea (midbrain) Apneusis (pontine) Apnea (> 20 seconds midbrain) Cluster breathing (high medullary) Ataxic breathing (medulla) Cheyne-Stokes breathing - very rare Central hypercapnia

Signs of brain stem damage Loss of thermoregulatory control Weakness Anisicoria (3rd nerve, one side) Pupillary dilation (midbrain) Pinpoint pupils (pontine) Hypotension Loss of consciousness (reticular formation) Vestibular signs - circling, head tilt Facial nerve paresis



Neonatal Encephalopathy Signs of CNS disease Seizure-like behavior Marching type behavior Abnormal extensor tone Seizures Coma, death



"Pong" Neonatal Encephalopathy Treatment

Nutritional Not nursing Trophic feeding Parenteral Nutrition Respiratory Intranasal oxygen Caffeine Positive Pressure Ventilation Seizures Phenobarbital

"Pong" Neonatal Encephalopathy

- Hospital day 2
 - Seizures resolved with phenobarbital therapy
 - Began ventilation
- Hospital day 3 standing
- Hospital day 5 nursing from bottle, more aware
- Hospital day 6 off intranasal oxygen
- Hospital day 9 nursing from mare

"Pong" Neonatal Nephropathy

Creatinine level slow to drop

Above normal until hospital day 11

High fractional excretion of Na

As high as 2.18% - normal for neonatal foal <0.3%
Still > 1% at discharge (day 20)

Development of significant edema

Persisted until day 6

Neonatal Nephropathy

Second most common target - 45% Common disease states Mild acute tubular necrosis Mild tubular dysfunction Maldistribution of renal blood flow Less common disease states Severe acute tubular necrosis Irreversible acute damage Chronic renal disease



Neonatal Nephropathy

Oliguria Anuria Edema formation Fluid overload Weight gain Persistently elevated Cr Birth Cr slow to drop Abnormal fraction excretions High amikacin trough levels Slow response to fluid challenges





"Pong" Neonatal Gastroenteropathy

Fetal/neonatal diarrhea Retained meconium Too much abdominal fill for not being fed Abnormal abdominal palpation One loop of bowel thickened wall Day 7 began passing feces Frequency > 24 hours Enema dependent Day 17 resolved

Third most common target - 40%
 Especially when metabolic demands (digestion) are superimposed on hypoxemic ischemic episodes
 Predisposition to sepsis and SIRS
 Translocation of bacteria through the GI tract

Dysphagia Colic Abdominal distension Gastric reflux Diarrhea Constipation Dysmotility Dietary intolerance Milk replacer Other specie's milk Frozen mare's milk Fresh mare's milk



Mild indigestion

Failure to absorb colostrum and other nutrients
 Dysmotility

Ileus

- Diapedesis of blood into the lumen
- Mucosal edema

Epithelial necrosis


- Development of intussusceptions or structures
- Hemorrhagic gastritis or enteritis/colitis
- Pneumatosis intestinalis











"Pong" Metabolic Maladaptation

Hypoglycemia at admission – 44 mg/dl
Hyperglycemic on glucose infusion – 243 mg/dl
Glucose diuresis
Hyponatremia, hypochloremia, hypokalemia
Diuresis, plasma osmotic effects
Insulin therapy
Constant infusion regular insulin IV
Begun hospital day 2, weaned day 4

"Pong" Problems

Sepsis Bacteremia - Pantoea agglomerans Shock Neonatal Encephalopathy Central Respiratory failure – ventilation therapy Neonatal Nephropathy Neonatal Gastroenteropathy

"Pong" Problems

- Neonatal Metabolic Maladaptation
- Edema
- Urachitis
- Hepatomegaly
- LDN
- Patent Urachus
- Over at knees

Therapeutic Interventions in Neonates

Neonatal Encephalopathy Therapy - CNS



DMSO

Mannitol

Thiamine

MgSO4




Neonatal Encephalopathy Therapy - CNS

Control seizures Phenobarbital Diazepam Midazolam Maintain cerebral perfusion Careful fluid replacement Maintaining blood pressure Inotropes and pressors



Neonatal Multisystem Maladaptation

Treat hypoxemia Intranasal Oxygen Oxygen carrying capacity of blood Oxygen delivery Normalized the pH, not CO2 Treat acidotic hypercapnia Caffeine Positive Pressure Ventilation Adequate perfusion Avoid fluid overload



Neonatal Multisystem Maladaptation

Maintain Nutrition
IV glucose

Avoid hyperglycemia
Parenteral nutrition
Enteral Nutrition

Treat infections



"Pong" Therapeutic interventions

- INO2
- Fluid boluses
- CRI Dobutamine
- Ticarcillin, clavulanic acid
- Plasma transfusion
- CRI glucose fluids
- CRI Insulin
- Phenobarbital

- Caffeine
- Positive pressure ventilation
- Parenteral Nutrition
- Trophic feedings
- Sucralfate
- Domperidone -- mare
- TMS , Cephalexin
- Bandaging



THE MALADJUSTED FOAL

Jon Palmer, VMD, DACVIM New Bolton Center, School of Veterinary Medicine University of Pennsylvania, Kennett Square, PA

Neonatology is a constantly evolving specialty. As our understanding of fetal and neonatal physiology and pathophysiology increase, our approach to therapy is modified and constantly refined. Approaches to therapy based on new ideas are introduced as those found to be based on incorrect assumptions are abandoned. One area currently undergoing reassessment is the pathogenesis is the neurologic disease and multiorgan maladaptation traditionally refered to as neonatal maladjustment syndrome.

Over the years, neonatal foals with neurologic signs have been referred to using various descriptive terms such as "barkers," "wanderers," "dummies," and most persistently as having Neonatal Maladjustment Syndrome (NMS). More recently NMS has been abandoned in favor of Hypoxic Ischemic Encephalopathy (HIE) because the former focuses attention on the behavioral aspects colored by the use of the term maladjustment in mental health. The neurologic disease of neonatal foals not only involves behavioral abnormalities but also other neurologic signs including changes in respiratory patterns/function, changes in muscle tone, changes in responsiveness, vestibular signs and autonomic disruption (loss of vascular control, loss of thermoregulation, inappropriate bradycardia, etc.). HIE not only was felt to describe the etiology, it implied a more generalized neurologic disruption. As it turns out, HIE is also not an ideal term. Although a hypoxic ischemic insult may be responsible for some cases, in most the underlying etiology is uncertain. We have followed the lead of MD neonatologists in simplifying the terminology to describe the organ system involved and the age group and not implying an etiology. Thus the term we use to describe neonatal foals with neurologic signs is Neonatal Encephalopathy (NE). We use the same convention for disorders of other organ systems: Neonatal Nephropathy (NN), Neonatal Gastroenteropathy (NG), etc. Hopefully this terminology will survive further expansion of our understanding of the underlying pathophysiology and will not need to be changed in the future.


Foals with Neonatal Encephalopathy (NE) may show changes in responsiveness, muscle tone, behavior, show evidence of brain stem damage or seizure-like behavior. Changes in responsiveness include hyperesthesia, hyperresponsiveness, hyperexcitability, hyporesponsiveness, periods of somnolence or unresponsiveness. Often foals go through a period of increased responsiveness followed by a period of decreased responsiveness. Changes in muscle tone include increased extensor tonus, hypotonia and other less common changes such as neurogenic myotonia or failure to protract front legs. Changes in behavior are very common and include loss of suckle response, loss of tongue curl, loss of tongue coordination, disorientation especially relative to the udder, aimless wandering, loss of affinity for the dam and abnormal vocalization. Although blindness is commonly assumed based on collisions with obstacles. I find that most foals can see but don't process what they see and thus run into obstacles. Foals with NE commonly have changes in respiratory patterns with central tachypnea, apneusis, apnea, cluster breathing, ataxic breathing, Cheyne-Stokes breathing or central hypercapnia. Other signs of brain stem damage include loss of thermoregulatory control, generalized weakness, anisocoria, pupillary dilation, pinpoint pupils, central hypotension, decreased responsiveness, difficult to arouse, loss of consciousness, vestibular signs (circling, head tilt), facial nerve paresis and a variety of other signs. Foals with NE have a wide variety of signs and degrees of severity. More than 90% of affected foals are normal within 10 days.

Foals may also develop Neonatal Nephropathy (NN). There is a wide spectrum of disease seen in cases of NN including incomplete transition from fetal renal physiology, water/sodium retention, mild tubular dysfunction (sodium wasting), abnormal excretion of drugs (e.g. high amikacin trough levels), acute tubular necrosis or decreased GFR. Often the signs of dysfunction are subtle and easily overlooked unless anticipated. Although almost always transient, on occasion significant acute damage may lead to chronic renal disease. These foals often have a decreased GFR as reflected by a slow decrease birth Creatinine or decreased creatinine clearance, delayed water excretion with edema formation and weight gain and slow response to fluid challenges.

Neonatal Gastroenteropathy (NG) can be manifested by a wide spectrum of signs ranging from mild indigestion with dysmotility and enema dependence to moderate disease with ileus, diapedesis of blood into the lumen and mucosal edema to severe disease with epithelial necrosis, intussusceptions, structures, hemorrhagic

gastritis/enteritis/colitis, and pneumatosis intestinalis. Even mild forms predispose to sepsis and SIRS with increased likelihood of translocation of bacteria. Like NN, often the signs of dysfunction are subtle and easily overlooked unless anticipated. The most common manifestation is dysmotility with meconium retention and lack of fecal passage for days (range 2-30 days). Despite fecal retention, an important aspect is lack of discomfort. Classically, foals with dysmotility will not return enema fluid or strain associated with rectal distension.

Often, affected foals have the triad of Neonatal Encephalopathy, Neonatal Nephropathy and Neonatal Gastroenteropathy. Other problems seen include metabolic maladaptation, autonomic failure and other systemic problems. Most of these foals have no clear history of an intrauterine hypoxic ischemic insult but certainly have had some intrauterine challenge. This intrauterine challenge may be fetal inflammation and not always fetal hypoxia ischemia. There is a connection between placentitis and many neonatal diseases and there is a protective effect of treatment. For many years we have suspected that the occurrence of placentitis is important in predisposing to neonatal diseases. In human medicine, intrauterine sepsis has been connected to early termination of pregnancy (prematurity) and experimental models have recently reinforced this connection. But the connection between placentitis and neonatal problems goes far beyond prematurity based on preliminary data from an ongoing study. Disruption of the intrauterine environment may be the initiator of many serious neonatal diseases. The inflammatory response may directly affect placental sufficiency or the inflammatory cascade accompanying the placentitis may have secondary adverse consequences for the fetus. On the other hand, the up-regulation of the fetal inflammatory response to septic challenges.



In a preliminary analysis of an observational retrospective study of the relationship between occurrence of placentitis and neonatal diseases and the effect of therapy we have found a significant connection between neonatal diseases and untreated placentitis. There is a strong association of placentitis and NE, NN and NG. This strong association supports the hypothesis that placentitis is the cause of these diseases. In addition prepartum treat of the mare for placentitis appears to protect against development of these diseases. The commonly utilized therapy of antimicrobials, NSAIDs and progestins all seemed to contribute to this protective affect. Surprisingly, treatment, independent of the presence of placentitis, showed a trend to protect against sepsis suggesting that something other than placentitis which responded to treatment could predispose the foal to sepsis. Alternately, treatment of the mare might decrease the exposure of the neonatal foal to factors that predispose to sepsis. This trend will be explored further as more cases are added to this data set. Although bacteremia was more likely in foals from mares with untreated placentitis, prepartum treatment of the mares did not protect from sepsis. Treatment of mares with placentitis significantly increased the odds of having a foal without any of the neonatal problems.

So the bad news is placentitis, a prevalent, recurring problem in many of our mares, is a major cause of some of the most serious neonatal diseases we treat. It may not be the only cause of these diseases but it significantly contributes to morbidity in our foals. The good news is that the commonly utilized therapy of placentitis in mares will protect foals from these diseases. So the take home message is that mares with suspect placentitis should be treated prepartum with the traditional therapy of TMS, ReguMate® and flunixin to

prevent development of common neonatal diseases in their foals. It is nice to have clinical impressions reinforced by clinical studies.

So how should we treat foals with this complex syndrome? Maintaining cerebral perfusion, achieved by careful fluid replacement and by the careful use of inopressors are the most important goals of therapy. It is also vital to maintain oxygen delivery and prevent catabolism. These goals should be achieved by delivering intranasal oxygen insufflation when necessary, enhancing pulmonary gas exchange with postural support, maintaining hematocrit above 20%, maintaining perfusion as above, supplying adequate exogenous glucose initially and if enteral nutrition is not possible within 24 hours, parenteral nutrition. So these foals may need fluids (be careful to avoid overhydation), oxygen, glucose and occasionally inotropes and pressors.

There have been a number of other favorite therapies used and although I have tried many, I have never been overly impressed and I feel we have little rational grounded in evidence for most of them. Free radical scavengers (DMSO, mannitol) have been used to minimize reperfusion injury, and they may be appropriate within minutes after relieving a dystocia during birth resuscitation but if treatment is not given within an hour or so of the insult it will not help. Clinicians often treat cerebral edema that "must be present." My experience parallels that of MDs who note that cerebral edema, when present, is an epiphenomena. It is a byproduct of severe disease and not part of the genesis. In survivable disease it doesn't seem to play a role. When a hypoxic ischemic insult is the cause, it may result in cellular edema and not cerebral edema unless it is very severe and the primary damage is fatal. Many clinicians use DMSO or mannitol routinely. I stopped using these treatments more than a decade ago. I did look back at about 300 cases and found using no treatment was effective or even a little better as gauged by survival to discharge than using either of these drugs. Thiamine has been used for its cerebral protective effect, but I don't think it aids recovery. Its supplementation is probably more useful as an aid to metabolism when high levels of dextrose are given especially in the face of hypermetabolism.

In the past I treat NE foals with MgSO₄, however its efficacy is unproven and MgSO₄ may be, in fact, contraindicated. The MgSO4 story is very interesting. It was originally suggested as a therapy to prevent NE in babies when a retrospective study showed that women preeclampsia who were treated with MgSO4 near the end of their pregnancy had a lower risk of having babies with NE. Its possible therapeutic use is bolstered by the knowledge that it will block Ca channels which will in theory prevent neurocyte damage secondary to hypoxic ischemic insults. However, several prospective therapeutic trials of the use of MgSO4 in late pregnancy in women have found that the use of magnesium increases the risk of severe neurologic disease in babies. It is actually preeclampsia which has the protective effect. It is possible that in smaller doses MgSO4 may have a protective effect against damage caused by hypoxic ischemic insults but in using it in foals we are not sure what dose might be toxic and which may be protective and as in human medicine, I have questioned how many foals with NE actually suffer from a hypoxic ischemic insult. So I no longer use MgSO4 to treat NE (*primum non nocere*).

With the recent idea that the underlying etiology is FIRS it is logical to consider anti-inflammatory drugs. As I believe that the insult occurs prenatal and the turned on inflammatory state helps the neonate resist antenatal infections, I don't currently use anti-inflammatory drugs in these cases. With a recovery rate of 85-90% with supportive care alone, any additional therapy would have to be very good or significantly shorten the course to make its use worthwhile.

Seizure-like activity should be prevented to minimize the possibility of ongoing damage. Phenobarbital is my standard therapy, despite its side effects which if anticipated can be minimized. Phenobarbital will cause a drop in core body temperature, a decrease in respiratory drive sometimes inducing hypercapnia and it may potentiate hypotension resulting in deterioration of perfusion. All of these side effects can be minimized by early intervention. Phenobarbital can be given repeatedly until seizures are controlled, infused over 15-20 minutes with a peak activity at 45 minutes. Once the seizures are controlled, in rare cases it may be necessary to repeat the dose in 6 to 12 hours. The half-life of phenobarbital in some foals may be >200 hours (others may have faster clearance) making maintenance unnecessary and even contraindicated. The degree of sedation achieved may be prolonged. If phenobarbital fails, phenytoin may be tried. Recently it has been suggested that midazolam might make a better choice. I have not adopted this therapy primarily because it is my goal to insure cerebral perfusion and it is well known that midazolam decreases cerebral perfusion significantly within minutes of administration. There is enough concern about midazolam's adverse effects in human neonatology that it has been recommended that it only be used in experimental trials. My feeling again is *primum non nocere*.